These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 26538165)

  • 1. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.
    Kickingereder P; Sahm F; Radbruch A; Wick W; Heiland S; Deimling Av; Bendszus M; Wiestler B
    Sci Rep; 2015 Nov; 5():16238. PubMed ID: 26538165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
    Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
    Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
    Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
    Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
    Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
    Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    Eur Radiol; 2019 Feb; 29(2):745-758. PubMed ID: 30003316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.
    Metellus P; Colin C; Taieb D; Guedj E; Nanni-Metellus I; de Paula AM; Colavolpe C; Fuentes S; Dufour H; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
    J Neurooncol; 2011 Dec; 105(3):591-600. PubMed ID: 21643985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
    Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
    Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
    Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A
    Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.
    Tatekawa H; Hagiwara A; Uetani H; Yao J; Oughourlian TC; Bahri S; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Pope WB; Salamon N; Ellingson BM
    J Neurooncol; 2020 Sep; 149(2):337-346. PubMed ID: 32929644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
    Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
    AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.
    Yao J; Chakhoyan A; Nathanson DA; Yong WH; Salamon N; Raymond C; Mareninov S; Lai A; Nghiemphu PL; Prins RM; Pope WB; Everson RG; Liau LM; Cloughesy TF; Ellingson BM
    Neuro Oncol; 2019 Sep; 21(9):1184-1196. PubMed ID: 31066901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Immunogenetic Properties of Glial Tumors with Advanced Magnetic Resonance Imaging Findings.
    Gezer B; Mutlukan A; Sahinoglu M; Karabagli PN; Koktekir E; Karabagli H
    Turk Neurosurg; 2020; 30(3):422-427. PubMed ID: 32091123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of IDH and TERTp mutations using dynamic susceptibility contrast MRI with deep learning in 162 gliomas.
    Buz-Yalug B; Turhan G; Cetin AI; Dindar SS; Danyeli AE; Yakicier C; Pamir MN; Özduman K; Dincer A; Ozturk-Isik E
    Eur J Radiol; 2024 Jan; 170():111257. PubMed ID: 38134710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH-1R132H mutation status in diffuse glioma patients: implications for classification.
    Wang PF; Liu N; Song HW; Yao K; Jiang T; Li SW; Yan CX
    Oncotarget; 2016 May; 7(21):31393-400. PubMed ID: 27120786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
    Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.
    Darlix A; Deverdun J; Menjot de Champfleur N; Castan F; Zouaoui S; Rigau V; Fabbro M; Yordanova Y; Le Bars E; Bauchet L; Gozé C; Duffau H
    J Neurooncol; 2017 May; 133(1):37-45. PubMed ID: 28434111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI.
    Hagiwara A; Tatekawa H; Yao J; Raymond C; Everson R; Patel K; Mareninov S; Yong WH; Salamon N; Pope WB; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
    Sci Rep; 2022 Jan; 12(1):1078. PubMed ID: 35058510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data.
    Mazurowski MA; Clark K; Czarnek NM; Shamsesfandabadi P; Peters KB; Saha A
    J Neurooncol; 2017 May; 133(1):27-35. PubMed ID: 28470431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.